Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12424269 | 0.83 | EPHX2 (0.33) | EPHX2OPRM1DPP8DPP7 | |
| SCHEMBL3532818 | 0.83 | HRH3 (0.39) | HRH3OPRM1KDM4E | |
| SCHEMBL3532821 | 0.83 | HRH3 (0.39) | HRH3OPRM1KDM4E | |
| SCHEMBL178291 | 0.81 | HRH3 (0.43) | HRH3EPHX2 | |
| SCHEMBL23797644 | 0.79 | CYP1A2 (0.47) | HRH3 | |
| SCHEMBL24040238 | 0.79 | HRH3 (0.40) | HRH3OPRM1 | |
| SCHEMBL25090324 | 0.79 | HRH3 (0.37) | HRH3OPRM1 | |
| SCHEMBL19860547 | 0.79 | SIGMAR1 (0.44) | HRH3KDM4E | |
| SCHEMBL21414332 | 0.79 | HRH3 (0.41) | HRH3OPRM1KDM4EDPP8 | |
| SCHEMBL14174929 | 0.79 | KDM4E (0.37) | HRH3EPHX2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023220129-A1 | BENZOYPARAZINE PYRAZINES ANE THEIR USES | FOGHORN THERAPEUTICS INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-11053235-B2 | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases | Janssen Sciences Ireland Unlimited Company (IE) | 2021-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053235-B2 | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases | DPYD, TYMP, HAVCR2 | HRH3 1159/4885EPHX2 3184/4885OPRM1 4577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.